PURPOSE: To evaluate the effects of the activation of endogenous angiotensin-converting enzyme 2 (ACE2) using the compound diminazene aceturate (DIZE) in an experimental model of glaucoma in Wistar rats. METHODS: DIZE (1 mg/kg) was administered daily, either systemically or topically, and the IOP was measured weekly. To examine the role of the Mas receptor in the effects of DIZE, the Ang-(1-7) antagonist A-779 was co-administered. Drainage of the aqueous humor was evaluated by using scintigraphy. The analysis of ACE2 expression by immunohistochemistry and the counting of retinal ganglion cells (RGCs) were performed in histologic sections. Additionally, the nerve fiber structure was evaluated by transmission electron microscopy. RESULTS: The systemic administration and topical administration (in the form of eye drops) of DIZE increased the ACE2 expression in the eyes and significantly decreased the IOP of glaucomatous rats without changing the blood pressure. Importantly, this IOP-lowering action of DIZE was similar to the effects of dorzolamide. The antiglaucomatous effects of DIZE were blocked by A-779. Histologic analysis revealed that the reduction in the number of RGCs and the increase in the expression of caspase-3 in the RGC layer in glaucomatous animals were prevented by DIZE. This compound also prevented alterations in the cytoplasm of axons in glaucomatous rats. In addition to these neuroprotective effects, DIZE facilitated the drainage of the aqueous humor. CONCLUSIONS: Our results evidence the pathophysiologic relevance of the ocular ACE2/Ang-(1-7)/Mas axis of the renin-angiotensin system and, importantly, indicate that the activation of intrinsic ACE2 is a potential therapeutic strategy to treat glaucoma.
PURPOSE: To evaluate the effects of the activation of endogenous angiotensin-converting enzyme 2 (ACE2) using the compound diminazene aceturate (DIZE) in an experimental model of glaucoma in Wistar rats. METHODS:DIZE (1 mg/kg) was administered daily, either systemically or topically, and the IOP was measured weekly. To examine the role of the Mas receptor in the effects of DIZE, the Ang-(1-7) antagonist A-779 was co-administered. Drainage of the aqueous humor was evaluated by using scintigraphy. The analysis of ACE2 expression by immunohistochemistry and the counting of retinal ganglion cells (RGCs) were performed in histologic sections. Additionally, the nerve fiber structure was evaluated by transmission electron microscopy. RESULTS: The systemic administration and topical administration (in the form of eye drops) of DIZE increased the ACE2 expression in the eyes and significantly decreased the IOP of glaucomatousrats without changing the blood pressure. Importantly, this IOP-lowering action of DIZE was similar to the effects of dorzolamide. The antiglaucomatous effects of DIZE were blocked by A-779. Histologic analysis revealed that the reduction in the number of RGCs and the increase in the expression of caspase-3 in the RGC layer in glaucomatous animals were prevented by DIZE. This compound also prevented alterations in the cytoplasm of axons in glaucomatousrats. In addition to these neuroprotective effects, DIZE facilitated the drainage of the aqueous humor. CONCLUSIONS: Our results evidence the pathophysiologic relevance of the ocular ACE2/Ang-(1-7)/Mas axis of the renin-angiotensin system and, importantly, indicate that the activation of intrinsic ACE2 is a potential therapeutic strategy to treat glaucoma.
Entities:
Keywords:
ACE2 activation; Mas receptor; angiotensin-(1-7); eyes; glaucoma; renin-angiotensin system
Authors: Robson A S Santos; Anderson J Ferreira; Ana Paula Nadu; Aline N G Braga; Alvair Pinto de Almeida; Maria José Campagnole-Santos; Ovidiu Baltatu; Radu Iliescu; Timothy L Reudelhuber; Michael Bader Journal: Physiol Genomics Date: 2004-05-19 Impact factor: 3.107
Authors: Tatiane M Murça; Patrícia L Moraes; Carolina A B Capuruço; Sérgio H S Santos; Marcos B Melo; Robson A S Santos; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada; Anderson J Ferreira Journal: Regul Pept Date: 2012-05-14
Authors: M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton Journal: Circ Res Date: 2000-09-01 Impact factor: 17.367
Authors: Robson A S Santos; Ana C Simoes e Silva; Christine Maric; Denise M R Silva; Raquel Pillar Machado; Insa de Buhr; Silvia Heringer-Walther; Sergio Veloso B Pinheiro; Myriam Teresa Lopes; Michael Bader; Elizabeth P Mendes; Virgina Soares Lemos; Maria Jose Campagnole-Santos; Heinz-Peter Schultheiss; Robert Speth; Thomas Walther Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 11.205
Authors: Philipp K Haber; Minghao Ye; Jan Wysocki; Christoph Maier; Syed K Haque; Daniel Batlle Journal: Hypertension Date: 2014-01-20 Impact factor: 10.190
Authors: Luana O Prata; Carolina R Rodrigues; Jéssica M Martins; Paula C Vasconcelos; Fabrício Marcus S Oliveira; Anderson J Ferreira; Maria da Glória Rodrigues-Machado; Marcelo V Caliari Journal: Exp Biol Med (Maywood) Date: 2016-08-21
Authors: Rodrigo A Fraga-Silva; Fabrizio Montecucco; Fabiana P Costa-Fraga; Alessio Nencioni; Irene Caffa; Maiia E Bragina; François Mach; Mohan K Raizada; Robson A S Santos; Rafaela F da Silva; Nikolaos Stergiopulos Journal: Vascul Pharmacol Date: 2015-08-22 Impact factor: 5.773
Authors: Sean E Thatcher; Xuan Zhang; Deborah A Howatt; Frederique Yiannikouris; Susan B Gurley; Terri Ennis; John A Curci; Alan Daugherty; Lisa A Cassis Journal: Arterioscler Thromb Vasc Biol Date: 2014-10-09 Impact factor: 8.311